5 Best Emerging Markets Stocks to Buy According to Analysts

3. HUTCHMED (China) Limited (NASDAQ:HCM)

Average Analyst Price Target as of February  27: $28.08

Upside Potential as of February 27: 75.61%

Number of Hedge Fund Holders: 7

HUTCHMED (China) Limited (NASDAQ:HCM) is a commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

In March 2023, HUTCHMED (China) Limited (NASDAQ:HCM) closed an exclusive license agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) to further the global development, commercialization, and manufacture of fruquintinib outside China. The company received a $400 million upfront payment in April 2023 and is eligible for up to $730 million in additional potential payments.

On November 8, HUTCHMED (China) Limited (NASDAQ:HCM) announced that its partner Takeda received approval from the FDA for FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancers.